This study aims to see if a new drug called ensartinib works better and is safer than the standard drug crizotinib for people with a specific type of advanced lung cancer (ALK-positive NSCLC). It will involve about 290 adults who have had up to one prior chemotherapy treatment. T…
Phase: PHASE3 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC